MARKET

AIMT

Aimmune
AIMT
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-8.6826
3832.22
12.55
2,257,375,397.58
Inflation: Shoppers, Get Ready to Pay More for Coffee, Beer, Bread and Snacks
Bloomberg · 07/30 06:00
Unlocking Unilever's Value Could Be the Next Big Thing for Activist Hedge Funds
Bloomberg · 07/16 05:00
Supreme Court Backs Nestle, Cargill on Child-Slavery Suit
Bloomberg · 06/17 20:02
Nestle Eyes Nature’s Bounty Acquisition to Boost Vitamin Sales
After ditching big chunks of its chocolate and ice cream businesses, Nestle SA Chief Executive Officer Mark Schneider is embracing healthier living by bulking up on vitamins and supplements.
Bloomberg · 04/26 08:22
Contactless Coffee
Nestle wants to get in on the back-to-office push with new contactless Nespresso machines (Source: Quicktake)
Bloomberg · 04/05 21:59
Wall Street Breakfast: Anticipation Builds For iPhone 12
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Anticipation builds for iPhone 12Wedbush is calling today's Apple (AAPL) iPhone event a "once in a decade" potential launch, and the stock is responding accordingly. Shares are up 2% premarket, following a 6.4% advance on Monday, amid expectations that it will be the first iPhone with full 5G capacity and cheaper than last year's devices. Analyst Daniel Ives predicts four iPhone models: 5.4-inch OLED display (starting price: $699); 6.1-inch OLED display ($799), 6.1-inch iPhone Pro OLED
Seekingalpha · 10/13/2020 11:04
Nestle reports 84% holding in Aimmune Therapeutics
Société des Produits Nestlé S.A. ((SPN)), a Nestle (NSRGY) subsidiary announces the results of the tender offer, to purchase all of the outstanding shares of Aimmune Therapeutics' (AIMT) common stock for
Seekingalpha · 10/13/2020 06:16
Aimmune Therapeutics: Do Not Tender Your Shares To Nestle
AIMT's stock fell precipitously amid the COVID-19 pandemic, despite receiving FDA approval for its Palforzia treatment (the first FDA approved treatment for peanut allergies).Nestle has commenced a tender offer to purchase shares of AIMT at $34.50 per share and it is trying to take advantage of the unwarranted selloff.Given recent developments with AIMT and its competitor, DBV Technologies, I believe this offer price is woefully inadequate.
Seekingalpha · 09/21/2020 10:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AIMT. Analyze the recent business situations of Aimmune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AIMT stock price target is 24.75 with a high estimate of 34.50 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 259
Institutional Holdings: 52.86M
% Owned: 80.76%
Shares Outstanding: 65.45M
TypeInstitutionsShares
Increased
70
4.48M
New
48
957.03K
Decreased
34
3.97M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Independent Director
Mark McDade
President/Chief Executive Officer/Director
Jayson Dallas
Chief Financial Officer
Eric Bjerkholt
General Counsel/Secretary
Douglas Sheehy
Other
Daniel Adelman
Other
Andrew Oxtoby
Independent Director
Greg Behar
General Manager
Sue Barrowcliffe
Independent Director
Patrick Enright
Independent Director
Kathryn Falberg
Independent Director
Brett Haumann
Independent Director
Mark Iwicki
Independent Director
Stacey Seltzer
No Data

Webull offers kinds of Aimmune stock information, including NASDAQ:AIMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIMT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIMT stock methods without spending real money on the virtual paper trading platform.